Drugs / Artichoke WPC
Artichoke WPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02076672 | Nov 2019 → Apr 2020 | asbestosis | Ontario Clinical Oncology Group (OCOG) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Artichoke WPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02076672 ↗ |
| Known as | Artichoke Whole Phytocomplex Concentrate | “Artichoke Whole Phytocomplex Concentrate (Artichoke WPC)” NCT02076672 ↗ |
| Known as | AWPC | “an artichoke freeze-dried extract (AWPC) as potential complementary preventive/early stage treatment agent for mesothelioma.” PMID 35987988 ↗ Aug 2022 |
| Route | Oral | “Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner.” NCT02076672 ↗ |